Work Here?
Work Here?
Work Here?
Amylyx Pharmaceuticals develops treatments for neurodegenerative diseases, focusing on conditions like Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's Disease (ALZ). Their main product, AMX0035, is currently undergoing clinical trials, including the CENTAUR ALS trial, which showed significant benefits for ALS patients in a controlled study. They are also conducting the PEGASUS trial to assess AMX0035's effectiveness for Alzheimer's patients. Unlike many competitors, Amylyx emphasizes rigorous clinical evaluation and community engagement, such as awareness campaigns for ALS. The company's goal is to bring effective therapies to market to improve patient outcomes.
Company Stage
IPO
Employees
51-200
Industries
Biotechnology, Healthcare
Total Funding
$166.7M
Headquarters
Cambridge, Massachusetts
Founded
2013
Help us improve and share your feedback! Did you find this helpful?
Find jobs on Simplify and start your career today